Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:002773)

SHE:002773 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	3,436	5,690	4,702	3,585	2,939	3,328
Trading Asset Securities	2,640	-	-	100	200	-
Cash & Short-Term Investments	6,076	5,690	4,702	3,685	3,139	3,328
Cash Growth	20.00%	21.00%	27.59%	17.41%	-5.67%	45.71%
Accounts Receivable	198.06	177.85	160.41	160.69	204.63	346.2
Other Receivables	11.75	23.04	28.81	27.94	43.59	25.57
Receivables	209.81	200.89	189.22	188.63	248.22	371.77
Inventory	364.32	386.86	403.61	330.96	295.62	239.64
Other Current Assets	47.55	11.56	10.63	24.16	15.89	22.77
Total Current Assets	6,698	6,289	5,306	4,229	3,699	3,962
Property, Plant & Equipment	2,320	2,353	2,411	2,553	2,097	1,781
Long-Term Investments	16.31	16.44	16.78	16.98	17.73	18.35
Goodwill	-	-	-	-	-	214.84
Other Intangible Assets	279.27	286.89	316.8	331.14	278.21	294.16
Long-Term Deferred Tax Assets	215.83	259.46	358.08	486.31	545.66	430.01
Long-Term Deferred Charges	127.78	123.24	99.33	70.47	84.67	55.56
Other Long-Term Assets	15.4	14.48	22.01	33.93	233.89	245.29
Total Assets	9,673	9,342	8,530	7,721	6,956	7,001
Accounts Payable	243.92	297.16	344.03	409.54	343.13	288.87
Accrued Expenses	43.05	233.88	203.64	169.59	174.63	193.52
Current Portion of Leases	1.43	1.73	0.53	1.6	2.57	-
Current Income Taxes Payable	60.38	13.31	9.82	19.69	16.49	37.45
Current Unearned Revenue	9.76	8.92	5.1	9.14	8.39	11.84
Other Current Liabilities	227.34	99.98	91.31	84.1	122.16	448.02
Total Current Liabilities	585.89	654.99	654.43	693.66	667.37	979.7
Long-Term Leases	2.31	3.47	1.48	3.27	4.43	-
Long-Term Unearned Revenue	25.75	23.58	22.94	30.3	25.51	51.4
Long-Term Deferred Tax Liabilities	13.33	13.03	7.94	5.14	2.06	2.37
Other Long-Term Liabilities	0.24	-	30.96	81.48	151.71	211.88
Total Liabilities	627.52	695.07	717.76	813.85	851.08	1,245
Common Stock	919.87	919.78	919.46	919.46	919.46	919.46
Additional Paid-In Capital	1,998	1,997	1,990	1,994	1,986	1,981
Retained Earnings	6,138	5,738	4,896	3,989	3,185	2,856
Comprehensive Income & Other	-1.85	-1.33	-1.34	-1.05	-0.83	-0.4
Total Common Equity	9,055	8,653	7,804	6,902	6,090	5,756
Minority Interest	-9.46	-6.34	7.89	5.07	15.24	-
Shareholders' Equity	9,045	8,647	7,812	6,907	6,105	5,756
Total Liabilities & Equity	9,673	9,342	8,530	7,721	6,956	7,001
Total Debt	3.74	5.2	2.01	4.87	7	-
Net Cash (Debt)	6,073	5,684	4,700	3,681	3,132	3,328
Net Cash Growth	19.97%	20.94%	27.70%	17.52%	-5.88%	45.72%
Net Cash Per Share	6.59	6.20	5.13	4.02	3.42	3.82
Filing Date Shares Outstanding	919.87	919.78	919.46	919.46	919.46	919.46
Total Common Shares Outstanding	919.87	919.78	919.46	919.46	919.46	919.46
Working Capital	6,112	5,634	4,651	3,535	3,031	2,982
Book Value Per Share	9.84	9.41	8.49	7.51	6.62	6.26
Tangible Book Value	8,775	8,366	7,487	6,571	5,812	5,247
Tangible Book Value Per Share	9.54	9.10	8.14	7.15	6.32	5.71
Buildings	-	2,126	1,989	1,785	1,137	-
Machinery	-	1,271	1,236	1,088	830.91	-
Construction In Progress	-	112.35	166.54	475.88	808.69	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.